RESUMEN
: Type 2A sub-type of Von Willebrand disease (VWD) is characterized by the loss of high molecular weight multimers. Several plasma-derived Von Willebrand factor concentrates (PD-VWFC) are available for treatment and recently a recombinant VWF concentrate (rVWFC) has been approved for use in VWD for adults in the United States. We describe a patient with Type 2A VWD who had persistent refractory epistaxis despite treatment with PD-VWFC. We describe differences in VWF multimeric composition and Factor VIII (FVIII) levels after plasma-derived and rVWF concentrates. Despite similar VWF levels, VWF multimeric composition after PD-VWFC remained abnormal while it corrected with rVWFC. Post-PD-VWFC, high levels of FVIII were seen, which were not observed after rVWFC. Recombinant VWFC may offer some advantages over PD-VWFC. This finding needs to be confirmed in larger studies.
Asunto(s)
Enfermedad de von Willebrand Tipo 2/tratamiento farmacológico , Factor de von Willebrand/uso terapéutico , Adulto , Proteínas Sanguíneas/uso terapéutico , Epistaxis/etiología , Factor VIII/análisis , Humanos , Multimerización de Proteína , Proteínas Recombinantes/uso terapéutico , Estados Unidos , Factor de von Willebrand/aislamiento & purificaciónRESUMEN
BACKGROUND: One of the most common rare inherited bleeding disorders, congenital factor VII (FVII) deficiency typically has a milder bleeding phenotype than other rare bleeding disorders. Categorizing severity in terms of factor activity associated with hemophilia (severe <1%, moderate 1%-5%, mild 6%-40%) has led to the observation that bleeding phenotype does not follow closely with FVII activity. Over the past decade, large-scale global registries have investigated bleeding phenotype more thoroughly. The International Society on Thrombosis and Haemostasis has reclassified FVII deficiency as follows: severe, FVII <10%, risk of spontaneous major bleeding; moderate, FVII 10%-20%, risk of mild spontaneous or triggered bleeding; mild, FVII 20%-50%, mostly asymptomatic disease. CASE REPORTS: Eleven illustrative cases of congenital FVII deficiency adapted from clinical practice are described to demonstrate the variability in presentation and in relation to FVII activity levels. Severe FVII deficiency usually presents at a young age and carries the risk of intracranial hemorrhage, hemarthrosis, and other major bleeds. Moderate FVII deficiency tends to present later, often in adolescence and particularly in girls as they reach menarche. Milder disease may not be apparent until found incidentally on preoperative testing, during pregnancy/childbirth, or following unexplained bleeding when faced with hemostatic challenges. CONCLUSION: It is important for health care professionals to be aware of the new definitions of severity and typical presentations of congenital FVII deficiency. Failure to appreciate the risks of major bleeding, including intracerebral hemorrhage in those with FVII activity <10%, may put particularly young children at risk.
Asunto(s)
Factor VIII/uso terapéutico , Factor VII/metabolismo , Hemofilia A/diagnóstico , Fragmentos Fc de Inmunoglobulinas/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Enfermedad de von Willebrand Tipo 1/diagnóstico , Enfermedad de von Willebrand Tipo 1/terapia , Preescolar , Contusiones/diagnóstico , Contusiones/etiología , Estudios de Seguimiento , Hemofilia A/complicaciones , Hemofilia A/terapia , Humanos , Masculino , Medición de Riesgo , Resultado del Tratamiento , Enfermedad de von Willebrand Tipo 1/complicacionesRESUMEN
The psychosocial impact of hemophilia on activities was recently investigated in the Hemophilia Experiences, Results and Opportunities (HERO) study (675 people with hemophilia and 561 caregivers of children with hemophilia in 10 countries). The impact of hemophilia B may not be accurately reflected in the HERO results, as ~75% of respondents described issues affecting males with hemophilia A. To address the needs of this population, the Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) was developed as a pilot study in the United States in collaboration with the hemophilia community. The analysis reported here assessed engagement in recreational activities and changes to treatment regimens around activities as reported by 299 adults with hemophilia B and 150 caregivers of children with hemophilia B. Nearly all adults with hemophilia B (98%) experienced a negative impact on their participation in recreational activities due to hemophilia-related issues, and most caregivers (90%) reported that hemophilia B had a negative impact on their child's engagement in recreational activities. One of the main reasons identified for discontinuing past activities was the risk of bruising or bleeding (adults/children with hemophilia B, 49%/41%). In particular, adults with hemophilia B reported a history of activity-related bleeding, and most adults decreased their participation in high-risk activities as they aged. Substantial percentages of adults and children with hemophilia B (including mild/moderate severity) altered their treatment regimens to accommodate planned activities. These findings may help inform guidelines for individualizing treatment regimens around participation in recreational activities based on hemophilia severity, baseline factor level, and activity risk and intensity.
Asunto(s)
Cuidadores/psicología , Hemofilia B/psicología , Recreación/psicología , Adolescente , Adulto , Factores de Edad , Niño , Preescolar , Femenino , Hemofilia B/epidemiología , Hemofilia B/fisiopatología , Hemofilia B/terapia , Hemorragia/epidemiología , Hemorragia/fisiopatología , Hemorragia/psicología , Hemorragia/terapia , Humanos , Lactante , Masculino , Factores de Riesgo , Estados Unidos/epidemiologíaRESUMEN
The Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) initiative was launched in an effort to address specific gaps in the understanding of the psychosocial impact of mild-moderate-severe hemophilia B. The original Hemophilia Experiences, Results and Opportunities (HERO) qualitative study evaluated the needs of people with hemophilia A or B in multiple countries; however, a majority of participants had the more common moderate-severe hemophilia A. The B-HERO-S study was designed in collaboration with the hemophilia community to evaluate the needs of adults with hemophilia B and caregivers of children with hemophilia B, including affected women and caregivers of girls with hemophilia. The report presented here describes participant demographics and comorbidities, as well as treatment regimens and access to treatment. Bleeding symptoms were reported by 27% of mothers of children with hemophilia B who participated. Women were more likely than men to self-report arthritis and depression/anxiety as comorbidities associated with hemophilia B. More adults and children with hemophilia B were on routine treatment than on on-demand treatment, and a high percentage of adults with moderate hemophilia B received routine treatment (86%). Many adults with hemophilia B (78%) and caregivers (69%) expressed concern about access to factor in the next 5 years, and of adults with hemophilia B, women more commonly experienced issues with access to factor in the past than did men (72% vs 44%). The findings of the B-HERO-S study reveal potential unmet needs of some patients with mild-moderate hemophilia B, and the results may be leveraged to inform patient outreach by hemophilia treatment centers and education initiatives.
Asunto(s)
Atención a la Salud , Hemofilia B , Hemorragia , Educación del Paciente como Asunto , Índice de Severidad de la Enfermedad , Encuestas y Cuestionarios , Adolescente , Adulto , Niño , Preescolar , Estudios Transversales , Femenino , Hemofilia B/epidemiología , Hemofilia B/fisiopatología , Hemofilia B/psicología , Hemofilia B/terapia , Hemorragia/epidemiología , Hemorragia/fisiopatología , Hemorragia/psicología , Hemorragia/terapia , Humanos , Masculino , Factores Sexuales , Estados Unidos/epidemiologíaRESUMEN
Young adults with hemophilia face unique challenges during the transition to adulthood, including issues associated with switching from pediatric to adult hematology care, building mature interpersonal relationships, and establishing an independent career with an assurance of medical insurance coverage. A greater understanding of these challenges is essential for developing effective strategies to address the specific needs of this population. These challenges may be differentiated from those of older adults with hemophilia in large part because of more extensive childhood prophylaxis and safer factor products, resulting in fewer joint problems and lower rates of HIV and HCV infections. This analysis of the changing nature and unmet needs of today's young adults entering into adult hemophilia treatment centers, as well as potential strategies for optimally addressing these needs, was developed following roundtable discussions between patients, caregivers, hematologists, and other health care professionals participating in comprehensive care. Challenges identified among young adults with hemophilia include psychosocial issues related to maturity, personal responsibility, and increased independence, as well as concerns regarding when and with whom to share information about one's hemophilia, limited awareness of educational and financial resources, and a low perceived value of regular hematology care. The initiatives proposed herein highlight important opportunities for health care professionals at pediatric and adult hemophilia treatment centers, as well as national organizations, community groups, and career counselors, to address key unmet needs of this patient population.
Asunto(s)
Necesidades y Demandas de Servicios de Salud , Hemofilia A , Adulto Joven/psicología , Adolescente , Adulto , Factores de Edad , Instituciones de Atención Ambulatoria/provisión & distribución , Cuidadores/psicología , Consejo , Empleo , Femenino , Objetivos , Personal de Salud/psicología , Accesibilidad a los Servicios de Salud , Hemofilia A/complicaciones , Hemofilia A/tratamiento farmacológico , Hemofilia A/economía , Hemofilia A/psicología , Hemorragia/etiología , Hemorragia/terapia , Humanos , Vida Independiente , Relaciones Interpersonales , Masculino , Cooperación del Paciente , Relaciones Profesional-Paciente , Psicología , Psicología del Adolescente , Transición a la Atención de Adultos , Estados UnidosAsunto(s)
Craneofaringioma/cirugía , Hipopituitarismo/etiología , Complicaciones Posoperatorias , Trombosis de la Vena/etiología , Adolescente , Preescolar , Craneofaringioma/sangre , Desamino Arginina Vasopresina/administración & dosificación , Desamino Arginina Vasopresina/efectos adversos , Estrógenos/uso terapéutico , Femenino , Hemostáticos/administración & dosificación , Hemostáticos/efectos adversos , Terapia de Reemplazo de Hormonas/métodos , Humanos , Hipopituitarismo/sangre , Hipopituitarismo/terapia , Monitoreo Fisiológico/métodos , Progesterona/uso terapéutico , Factores de Riesgo , Trombofilia , Trombosis de la Vena/sangre , Trombosis de la Vena/terapia , Factor de von Willebrand/antagonistas & inhibidoresRESUMEN
INTRODUCTION: Pulmonary embolism in children is a rare, potentially life threatening condition. The clinical characteristics of pediatric pulmonary embolism have not been well studied and the exact incidence in children is not known. We report a case series of fourteen patients with pulmonary embolism and describe their clinical characteristics. MATERIALS AND METHODS: Inpatient and outpatient clinic charts of patients with proven pulmonary embolism (PE) followed at the Hemostasis and Thrombosis Center at Children's Hospital of Michigan were reviewed for relevant clinical and laboratory information. RESULTS: All patients with PE were symptomatic but accurate diagnosis of PE was often delayed in the outpatient setting. Screening testing with D-dimer was normal in 40% of patients. Acquired risk factors and lower extremity clots were more common in patients analyzed. Treatment regimens differed but most patients had resolution of pulmonary emboli on follow-up. CONCLUSIONS: A high index of suspicion is needed for the diagnosis of pediatric PE. D-Dimer may be normal in some children with PE. Pediatric multicenter trials are needed to evaluate clinical characteristics, risk factors, long-term outcome and effects of PE on pulmonary and cardiac function.